Schatz M
J Allergy Clin Immunol. 1984 Oct;74(4 Pt 2):606-16. doi: 10.1016/0091-6749(84)90114-3.
True allergic reactions to local anesthetics (LAs) probably make up no more than 1% of all adverse LA reactions. A diagnosis of true potential allergic reactivity is made difficult because (1) the history of the prior reaction may be vague or equivocal and (2) the lack of identification of the actual specific LA hapten-carrier complex limits the potential usefulness of immunologic tests. Nonetheless, since avoidance of LAs may be associated with substantial increased pain or increased risk and because true allergic reactions are rare, investigators and clinicians have used skin testing, incremental challenge, or both as a means of identifying a safe LA for a patient with a history of a prior adverse reaction. Review of the literature dealing with LA skin testing and incremental challenge suggests the following: (1) Skin testing with LAs may correlate with a history of an adverse reaction but may produce systemic adverse reactions, especially with undiluted drug. (2) Although false positive skin tests have been reported, most skin-tested patients who subsequently tolerate an LA have a negative skin test to that drug, and false negative skin tests have not been clearly documented. (3) Incremental challenge beginning with diluted LA is a safe and effective means of identifying a drug that a patient with a history of a prior adverse reaction can tolerate. (4) Current concepts of non-cross-reacting LA groups may be useful in the choice of a drug for use in skin testing and incremental challenge. (5) Preservatives in LAs may account for some but probably not the majority of adverse reactions to LAs. On the basis of this literature review, a practical protocol including dilutional skin testing and incremental challenge is presented for use in evaluating patients with prior adverse reactions to LAs.
对局部麻醉药(LA)的真正过敏反应可能仅占所有LA不良反应的1% 。真正潜在过敏反应的诊断很困难,原因如下:(1)既往反应的病史可能模糊不清或模棱两可;(2)缺乏对实际特定LA半抗原-载体复合物的鉴定,限制了免疫检测的潜在用途。尽管如此,由于避免使用LA可能会带来疼痛大幅增加或风险升高,而且真正的过敏反应很少见,研究人员和临床医生已采用皮肤试验、递增激发试验或两者兼用,作为为有既往不良反应史的患者确定安全LA的方法。对有关LA皮肤试验和递增激发试验的文献综述表明如下情况:(1)LA皮肤试验可能与不良反应史相关,但可能会产生全身不良反应,尤其是使用未稀释药物时。(2)尽管有假阳性皮肤试验的报告,但大多数随后耐受LA的皮肤试验患者对该药物的皮肤试验呈阴性,且假阴性皮肤试验尚未得到明确记录。(3)从稀释的LA开始进行递增激发试验,是确定有既往不良反应史的患者能够耐受的药物的安全有效方法。(4)目前关于无交叉反应LA组的概念,可能有助于选择用于皮肤试验和递增激发试验的药物。(5)LA中的防腐剂可能是一些LA不良反应的原因,但可能不是大多数不良反应的原因。基于这篇文献综述,提出了一个实用方案,包括稀释皮肤试验和递增激发试验,用于评估有既往LA不良反应的患者。